TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT05846724

Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma

Cause of deathFunding or business Automatic label, confidence 0.9, unverified. How labels are made.
“The lack of adequate funding has made it impossible to continue with the clinical study As this study was not initiated, no subject was included and no data was collected,thus no result can be obtained SPONSOR\_DECISION End of trial date:15 Oct 2025”

The sponsor’s own words in the registry.

Life of this trial

20232024202520262027Registered2023-04-27Planned start2024-02-01 (planned)Withdrawn (as of)2026-01-22

Vital statistics

Status
Withdrawn
Phase
Phase 2
Sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Sponsor type
University, hospital or other
Conditions
Kaposi Sarcoma; Classic Kaposi Sarcoma; Refractory Kaposi Sarcoma
Interventions
Pembrolizumab + Lenvatinib
Participants
0

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.